Denosumab, a RANKL-neutralizing antibody, is used as a therapeutic agent for osteoporosis [9], a giant cell tumor of bone; metastatic bone tumors; and other diseases in which osteoclast activity is increased, resulting in decreased bone density and bone destruction. The gene discussed is TNFSF11; the disease is osteoporosis.